Veritas In Silico ＜130A＞ announced on the 13th, a revision of the full-year Financial Estimates for the fiscal year ending December 2024, based on recent performance trends.

The revision of the full-year Financial Estimates for the fiscal year ending December 2024 (January - December 2024) has been adjusted to a business revenue of 0.189 billion yen, a operating profit of a 0.214 billion yen loss, a recurrent profit of a 0.235 billion yen loss, and a Net income of a 0.238 billion yen loss, with Net income per share revised to a loss of 37.39 yen.

The company is utilizing its drug discovery platform ibVIS(R) to conduct research on mRNA-targeted small molecule drug discovery in collaboration with multiple pharmaceutical companies. In the Financial Estimates announced on February 13, 2024, it was estimated that business revenue from contract payments would be calculated based on acquiring two new contracts during the fiscal year ending December 2024. Although negotiations for obtaining these two contracts are steadily progressing, the conclusion of the contracts is expected to take place in the next fiscal year (ending December 2025), leading to the revision of the Financial Estimates for the fiscal year ending December 2024.